January 6, 2023 03:22 PM ESTUpdated 03:47 PM
Pharma
FDA+

Ei­sai prices Alzheimer's drug at $26,500, be­low part­ner Bio­gen's Aduhelm

Kyle LaHucik

Senior Reporter

Ei­sai and Bio­gen will price their new Alzheimer’s treat­ment Leqem­bi at $26,500 per year, US CEO Ivan Che­ung tells End­points News. With out­cries over the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Fed­er­al ap­peals court says Te­va must delist Or­ange Book in­haler patents

A service from the Financial Times